Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 10th 2020

We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the results of the phase 2 trial evaluating the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis’ (ABSTRACT NUMBER: L06) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.

Question

  1. Could you give us an overview of the study you are presenting, and its efficacy and safety findings? (0:05)

Disclosure: Maria Cinta Cid discloses receiving consulting/advisory board fees from GSK, Abbvie and Janssen, lecturing fees from Vifor and a research grant from Kiniksa. Maria Cinta Cid was regional lead for the GiACTA trial (Riche) and co-PI for the KPL-301-C001 trial with mavrilimumab.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup